AP NEWS
Click to copy
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Click to copy
PRESS RELEASE: Paid content from Globe Newswire
Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Coherus BioSciences Management to Present at Jefferies 2019 Global Healthcare Conference

Coherus BioSciences, Inc.May 22, 2019

REDWOOD CITY, Calif., May 22, 2019 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq: CHRS), today announced that senior management will present at the Jefferies 2019 Global Healthcare Conference in New York City on Tuesday, June 5, 2019 at 10:00 a.m. ET.

The audio portion of the presentation will be available on the investors page of the Coherus BioSciences website at http://investors.coherus.com.

About Coherus BioSciences, Inc.

Coherus BioSciences is a leading biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales and marketing and clinical-regulatory development, Coherus BioSciences is positioned as a leader in the global biosimilar marketplace. Coherus BioSciences commercializes UDENYCA® (pegfilgrastim-cbqv) in the U.S. and has received regulatory approval for UDENYCA® in the European Union. Coherus BioSciences is advancing two late-stage clinical products towards commercialization, CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), and developing a robust pipeline of future products in ophthalmology (including CHS-3351, a ranibizumab biosimilar, and CHS-2020, an aflibercept biosimilar), as well as CHS-131, a small molecule for nonalcoholic steatohepatitis (NASH) and multiple sclerosis. For additional information, please visit www.coherus.com.

About Coherus BioSciences, Inc.

David S. ArringtonVP, Investor Relations & Corporate AffairsCoherus BioSciences, Inc.darrington@coherus.com+1 (650) 395-0196

All contents © copyright 2019 The Associated Press. All rights reserved.